Bilateral Cardiac Sympathetic Denervation for the Management of Electrical Storm  by Ajijola, Olujimi A. et al.
Journal of the American College of Cardiology Vol. 59, No. 1, 2012
© 2012 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00
Published by Elsevier Inc.CORRESPONDENCE
Research
Correspondence Bilateral Cardiac Sympathetic Denervationfor the Management of Electrical StormTo the Editor: The sympathetic nervous system plays an important
role in ventricular arrhythmogenesis. Left cardiac sympathetic
denervation (LCSD) decreases the incidence of ventricular ar-
rhythmias (VAs) and sudden cardiac death in patients with severe
VAs (1,2). However, when LCSD is ineffective in suppressing
VAs, adjunctive right cardiac sympathetic denervation may be an
option. In humans, the safety and feasibility of bilateral cardiac
sympathetic denervation (BCSD) in the management of VAs
remains unclear. The present study was undertaken to assess the
benefit of BCSD for the acute management of persistent VAs.
We reviewed the records of patients who underwent BCSD (or
right cardiac sympathetic denervation after prior LCSD failed to
control arrhythmias). Review of patient data was in accordance
with the guidelines of the institutional review board. These
patients presented with electrical storm characterized by incessant
ventricular tachycardia (VT) or repeated episodes of ventricular
fibrillation.
Five men and 1 woman were included in the study. The mean
age was 60.1 years (range: 47 to 75 years), and the mean left
ventricular ejection fraction was 25.8% (range: 15% to 40%) (Table 1).
Five patients presented with monomorphic VT (MMVT), and 1
patient had polymorphic VT. Of patients with MMVT, 4 had
undergone previous endocardial VT ablation, and 2 had undergone
epicardial VT ablation. The arrhythmia burden and number of
therapies (automated or external defibrillator shocks and antitachy-
cardia pacing episodes) experienced by each patient are shown in
Table 1.
After presentation, VAs persisted despite intensive investigation
and correction of all reversible causes. All patients received
maximal tolerated beta-blockade (metoprolol 50%, carvedilol 50%)
and amiodarone. Lidocaine and/or mexiletine was used in 50% of
patients. Other antiarrhythmic agents were contraindicated or had
failed previously. Among the 5 patients with MMVT, we per-
formed catheter ablation in 3, including 1 combined endocardial
and epicardial approach. One patient underwent 3 endocardial
ablations. In summary, all patients with MMVT underwent
catheter ablation (mean 2.2  0.5 ablations/patient) either before
or during the hospitalization that included BCSD. Thoracic
epidural anesthesia was used in 2 patients, with partial to no
response noted, despite repositioning of the epidural catheter. The
patients were all deemed poor transplantation candidates. Only
after these measures failed were patients considered for BCSD (or
right cardiac sympathetic denervation as an adjunct to prior
LCSD).
After BCSD, complete response was observed in 66.7% of
patients (4 of 6), while partial response was seen in 16.7% of
patients (1 of 6) and no response in 16.7% (1 of 6). Implantable
cardioverter-defibrillator shocks and antitachycardia pacing de-
creased to no shocks or episodes in 3 patients and decreased by
50% in 1 patient (Fig. 1, Table 1). External shocks decreasedfrom 11 to none in another patient. Frequencies of therapies before
and after BCSD are shown in Figure 1. Only 1 patient showed no
response to BCSD. All 5 patients who showed reductions in VAs
with BCSD survived to discharge (Table 1), while the only
nonresponder expired after withdrawal of care, at the family’s
request. After discharge, 2 deaths were noted (Table 1), neither of
which was related to arrhythmias. Patient 1 continued to have
heart failure exacerbations and elected to receive hospice care.
Patient #6 expired at home for unknown reasons. Interrogation of
his implantable cardioverter-defibrillator showed no atrial or VAs
before or at the time of death.
No significant electrocardiographic changes or events consistent
with adrenergic insufficiency were documented in patients subse-
quent to bilateral denervation. Operative complications occurred in
2 patients (post-operative heart failure and poor tolerance of single-
lung ventilation during video-assisted thoracoscopic surgery).
To our knowledge, this is the largest cohort of patients
undergoing BCSD reported to date. Limitations of this study
include its small size, which precludes broad conclusions re-
garding the applicability of these results. Furthermore, because
of the lack of randomization and the retrospective approach,
biases that may have been involved in the decision-making
process cannot be excluded.
Mechanisms underlying the benefit of BCSD may include the
interruption of adverse stellate ganglion remodeling or the miti-
gation of proarrhythmic neural signaling within the myocardium
or stellate ganglia. Multiple lines of evidence suggest a potent
antiarrhythmic effect of BCSD on ventricular myocardium. In
canine studies comparing left, right, and bilateral sympathectomy,
the most profound antiarrhythmic effects were seen with bilateral
sympathectomy (3,4). Studies on spinal cord stimulation and
thoracic epidural anesthesia (2,5,6), both of which decrease global
cardiac sympathetic activity, have shown a profound protective
effect. Compared with asystole and pulseless electrical activity, VT
and ventricular fibrillation are less frequent modes of sudden
cardiac death in patients after cardiac transplantation (7), because
these hearts are completely denervated.
Our study suggests that for patients with incessant VAs for
whom no other therapeutic options exist, BCSD may be beneficial.
This procedure does not appear to result in adverse outcomes.
Further studies examining the role of BCSD in suppressing human
arrhythmias are warranted.
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Figure 1 Acute Improvement in Therapies per Day (Numberof Therapies/Number of Days) Before and After BCSD
Therapies included antitachycardia pacing episodes and automated or
external defibrillation. BCSD  bilateral cardiac sympathetic denervation.T P
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